Thomas Von Erlach
Co-Founder & Chief Scientific Officer Vivtex
Thomas von Erlach, PhD co-founded Vivtex and joined as its Chief Scientific Officer when Vivtex was formed as a MIT spin-off in 2018. Prior to that he led the interdisciplinary efforts around gastrointestinal model systems for oral drug delivery applications at the Laboratory of Prof. Robert Langer and Prof. Giovanni Traverso at MIT. Dr von Erlach obtained his PhD from Imperial College London in Bioengineering and a BSc and MSc in Biochemistry and Biotechnology from ETH Zurich in Switzerland. His research interest include advanced in vitro models for drug development, oral drug delivery and gastrointestinal pharmacology. His work is published in several high impact journals such as Nature Materials, Nature Biomedical Engineering, and Nature Communications.
Seminars
- How to effectively design patient-centric peptide delivery formulations (oral vs injectable)?
- How to ensure novel peptide formulations can be scalable and cost efficient during the manufacturing process?
- Where will delivery innovations take the peptide field in the next 5 years?
The biopharmaceutical sector continues to innovate peptide discovery innovations, from new macrocycles to new delivery methods and are thriving on strategic alliances, which allow for cross-functional sharing of knowledge, and experience to advance peptide drugs to patients faster. Hear first-hand how investors and key biotechs are keeping up with the peptide momentum through investments, alliances and collaborations.
Key questions to be addressed include:
- How to strategize the complexities, risks and decision-making strategies for choosing the right platform to invest and advance innovative approaches in the peptide industry?
- What are the key areas and spaces that peptides can fill in the biotechnology sector?
- What does it take for a small biotech to survive and get noticed from an investor or big pharma?
- Highlighting the challenges in oral delivery
- Presenting solutions on how to overcome these challenges with focus on using high throughput screening approaches
- Demonstrating case studies examples of increasing oral exposure in dogs using next generation formulations
